论文部分内容阅读
探讨乙型肝炎病毒 (HBV)转基因小鼠模型筛选抗HBV药物的可行性。方法 选本室建立的HBV转基因小鼠 2 0只 ,随机分成两组 ,每组 10只。采用灌胃针灌胃法给药。对照组灌喂生理盐水 ,拉米夫定组灌喂拉米夫定 ,剂量为 10 0mg/kg ,每天 1次 ,连续灌 2 1d ,每 7d采血 1次。PCR检测血清中HBVDNA。结果 实验组用拉米夫定 1周后 2 0 %小鼠血清HBVDNA电泳带消失 ,2周后 ,70 %HBVDNA电泳带消失 ,3周后 ,所有小鼠血清HBVDNA电泳带消失 ,停药 1周后 ,再次检测血清HBVDNA ,78%小鼠血清HBVDNA电泳带又出现。结论 本室建立的HBV转基因小鼠模型验证了拉米夫定对HBV的抑制程度和持续时间 ,表明该模型可应用于抗HBV药物的筛选
To investigate the feasibility of screening anti-HBV drugs in hepatitis B virus (HBV) transgenic mouse model. Methods Twenty HBV transgenic mice were randomly divided into two groups (n = 10 in each group). Gavage with intragastric administration method. The control group was infused with normal saline. The lamivudine group was infused with lamivudine at a dose of 10 mg / kg once daily for 21 days and once every 7 days. PCR detection of serum HBVDNA. Results Serum HBVDNA electrophoresis bands disappeared in 20% of mice after 1 week of lamivudine treatment, and 70% of HBVDNA electrophoresis bands disappeared after 2 weeks. After 3 weeks, serum HBVDNA electrophoresis bands of all mice disappeared and stopped for 1 week After that, serum HBVDNA was detected again and 78% of the mice serum HBVDNA electrophoresis bands appeared again. Conclusion HBV transgenic mouse model established in this study validated the extent and duration of HBV inhibition by lamivudine, indicating that this model can be applied to the screening of anti-HBV drugs